Trends in Incidence of Prostate Cancer in Iran and Its 31 Provinces During 2003 - 2016

IF 0.4 Q4 ONCOLOGY

International Journal of Cancer Management Pub Date : 2023-12-05 DOI:10.5812/ijcm-136819

M. Nowroozi, Ehsan Mosa Farkhani, K. Hushmandi, E. Amini, Seyed Ali Momeni, Seyed Hassan Inanloo, S. Bokaie, L. Sharifi

{"title":"Trends in Incidence of Prostate Cancer in Iran and Its 31 Provinces During 2003 - 2016","authors":"M. Nowroozi, Ehsan Mosa Farkhani, K. Hushmandi, E. Amini, Seyed Ali Momeni, Seyed Hassan Inanloo, S. Bokaie, L. Sharifi","doi":"10.5812/ijcm-136819","DOIUrl":null,"url":null,"abstract":"Background: Prostate cancer is the most common malignancy in men, which is the second leading cause of cancer-related death. The prevalence of prostate cancer in Iran is lower than in Western and European countries. Objectives: Our study presents an updated incidence rate of prostate cancer in Iran and its provinces, displays its trends, and adds its spatial distribution to the literature. Methods: We investigate the age-standardized incidence rates (ASIRs) per annum of prostate cancer from 2003 to 2016 in Iran, using the data of the cancer registration available by the Ministry of Health and Medical Education. Crude incidence rates were calculated by dividing incident cases by the population of the whole country and each province which was available on the website of Iran Statistic Center. Age standardization was done by the World Health Organization (WHO) standard population and presented according to age and province. Results: The crude number of incident prostate cancer cases in Iran was 49 188 between 2003 and 2016. Age-standardized incidence rate of prostate cancer showed an increasing trend from 4.46 in 2003 to 18.44 per 100 000 in 2016. Mazandaran (29.57 per 100 000 in 2008) and Esfahan (27.5 per 100 000 in 2016 and 26.51 per 100 000 in 2015) were provinces with the highest reported ASIRs, while Sistan and Baluchestan province had the lowest mean of ASIR (1.59 per 100 000) in the period of the study. Conclusions: The incidence of prostate cancer displays an increase of more than 4 times at the end of the study period. However, the increase in coverage of data recording and greater access to diagnostic tests during these years are effective in the reported ASIRS, but the steep slope in the incidence trend of prostate cancer compared to other cancers in Iran shows its capacity to become one of the health problems that underscore the necessity of implementation of control and prevention programs, especially in high-incidence provinces.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2023-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Cancer Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5812/ijcm-136819","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Prostate cancer is the most common malignancy in men, which is the second leading cause of cancer-related death. The prevalence of prostate cancer in Iran is lower than in Western and European countries. Objectives: Our study presents an updated incidence rate of prostate cancer in Iran and its provinces, displays its trends, and adds its spatial distribution to the literature. Methods: We investigate the age-standardized incidence rates (ASIRs) per annum of prostate cancer from 2003 to 2016 in Iran, using the data of the cancer registration available by the Ministry of Health and Medical Education. Crude incidence rates were calculated by dividing incident cases by the population of the whole country and each province which was available on the website of Iran Statistic Center. Age standardization was done by the World Health Organization (WHO) standard population and presented according to age and province. Results: The crude number of incident prostate cancer cases in Iran was 49 188 between 2003 and 2016. Age-standardized incidence rate of prostate cancer showed an increasing trend from 4.46 in 2003 to 18.44 per 100 000 in 2016. Mazandaran (29.57 per 100 000 in 2008) and Esfahan (27.5 per 100 000 in 2016 and 26.51 per 100 000 in 2015) were provinces with the highest reported ASIRs, while Sistan and Baluchestan province had the lowest mean of ASIR (1.59 per 100 000) in the period of the study. Conclusions: The incidence of prostate cancer displays an increase of more than 4 times at the end of the study period. However, the increase in coverage of data recording and greater access to diagnostic tests during these years are effective in the reported ASIRS, but the steep slope in the incidence trend of prostate cancer compared to other cancers in Iran shows its capacity to become one of the health problems that underscore the necessity of implementation of control and prevention programs, especially in high-incidence provinces.

查看原文本刊更多论文

2003 - 2016 年伊朗及其 31 个省的前列腺癌发病率趋势

背景:前列腺癌是男性最常见的恶性肿瘤，是癌症相关死亡的第二大原因。伊朗的前列腺癌患病率低于西欧国家。目的:我们的研究介绍了伊朗及其各省前列腺癌的最新发病率，显示了其趋势，并将其空间分布添加到文献中。方法:利用伊朗卫生和医学教育部提供的癌症登记数据，调查2003 - 2016年伊朗每年前列腺癌的年龄标准化发病率(asir)。粗发病率由病例数除以伊朗统计中心网站上的全国和各省人口计算得出。年龄标准化由世界卫生组织(WHO)标准人口完成，按年龄和省份分列。结果:2003 - 2016年伊朗前列腺癌粗发病例数为49188例。前列腺癌年龄标准化发病率从2003年的4.46 / 10万上升至2016年的18.44 / 10万。马赞达兰(2008年为29.57 / 10万)和伊斯法罕(2016年为27.5 / 10万，2015年为26.51 / 10万)是报告ASIR最高的省份，而锡斯坦和俾路支斯坦省在研究期间的ASIR平均值最低(1.59 / 10万)。结论:前列腺癌的发病率在研究期结束时增加了4倍以上。然而，这些年来，数据记录覆盖率的增加和诊断测试的扩大在报告的ASIRS中是有效的，但是与伊朗其他癌症相比，前列腺癌发病率的急剧上升趋势表明，前列腺癌有能力成为健康问题之一，强调了实施控制和预防计划的必要性，特别是在高发病率省份。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Cancer Management ONCOLOGY-

CiteScore

1.10

自引率

0.00%

发文量

期刊介绍： International Journal of Cancer Management (IJCM) publishes peer-reviewed original studies and reviews on cancer etiology, epidemiology and risk factors, novel approach to cancer management including prevention, diagnosis, surgery, radiotherapy, medical oncology, and issues regarding cancer survivorship and palliative care. The scope spans the spectrum of cancer research from the laboratory to the clinic, with special emphasis on translational cancer research that bridge the laboratory and clinic. We also consider original case reports that expand clinical cancer knowledge and convey important best practice messages.